EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IL‐2 Free Expansion of T Cells with Immunofilaments

Marjolein Schluck iD, Lea Weiss, René Classens, Carl G Figdor, Roel Hammink iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202503766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Marjolein Schluck und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Interleukin-2, T-Lymphocytes, Antigen-Presenting Cells. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KWF Kankerbestrijding, Oncode Institute, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel biomaterial‐based cancer immunotherapeutic strategies, such as artificial antigen‐presenting cells (aAPCs), focus on activating T cells through molecular cues presented on synthetic constructs aiming to improve T cell activation and direct differentiation. To meet these aims, aAPC designs that allow control over the ratio and density of the stimulatory signals are crucial. In this study, we used polyisocyanopeptide based immunofilaments (IF) as nanosized aAPCs to study the influence of ratio and density of αCD3 and αCD28 on T cell expansion and phenotype. We observed differences in T cell expansion, cytokine production, and effector phenotype, dependent on both the density and ratio. Interestingly, supplementation with 30 to 1000 U/mL IL‐2 did not influence T cell expansion, cytokine production, or the effector phenotype of the optimal performing IFs. In contrast, IL‐2 supplementation increased the number of terminal effector T cells, increased TIM3 expression, and significantly increased the levels of Tregs in the culture. Taken together, these results suggest that careful finetuning of the density and ratio of stimulatory antibodies on IFs can omit the need for IL‐2 supplementation, which leads to a preferable phenotype. As such, our findings can be used to optimize T cell expansion protocols for ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2T-LymphocytesAntigen-Presenting CellsCell ProliferationLymphocyte ActivationHumansAnimalsCD3 ComplexCD28 Antigens

Stichwörter der Autor:innen

Interleukin‐2T cellsadoptive cell transfer (ACT)artificial antigen‐presenting cells (aAPCs)ex vivo expansion

Substanzen

Interleukin-2CD3 ComplexCD28 Antigens

Autor:innen und Institutionen

  • Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Oncode Institute, Nijmegen, The Netherlands.
  • Institute for Chemical Immunology, Nijmegen, The Netherlands.

ORCID-Profile: Marjolein Schluck, Roel Hammink

Förderung

  • KWF Kankerbestrijding
  • Oncode Institute
  • European Research Council

Zitieren

APA

Schluck, M., Weiss, L., Classens, R., Figdor, C. G., & Hammink, R. (2026). IL‐2 Free Expansion of T Cells with Immunofilaments. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503766

Vancouver

Schluck M, Weiss L, Classens R, Figdor CG, Hammink R. IL‐2 Free Expansion of T Cells with Immunofilaments. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503766

BibTeX
@article{Schluck2026,
  author = {Schluck, Marjolein and Weiss, Lea and Classens, René and Figdor, Carl G and Hammink, Roel},
  title = {IL‐2 Free Expansion of T Cells with Immunofilaments},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202503766}
}
Kostenlos starten →